{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:20:24Z","timestamp":1782372024313,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K14857"],"award-info":[{"award-number":["23K14857"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["19K08088"],"award-info":[{"award-number":["19K08088"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tri-weekly cisplatin and radiotherapy (CDDP\u2009+\u2009RT) is a standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) but is sometimes challenging to complete in older patients. Weekly CDDP\u2009+\u2009RT has shown mild toxicity compared to tri-weekly CDDP\u2009+\u2009RT for LA-HNSCC and is a promising option for older adults. We aimed to report the treatment outcomes and prognostic factors in patients with LA-HNSCC treated with weekly CDDP\u2009+\u2009RT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed patients aged\u2009\u2265\u200970\u00a0years who started weekly CDDP\u2009+\u2009RT for LA-HNSCC between July 2006 and October 2022. LA-HNSCC includes cancer in the oropharynx, hypopharynx, or larynx with a clinical stage of 3 or 4 without distant metastases based on the Union for International Cancer Control staging system 8th edition. The radiation dose of 70\u00a0Gy was delivered in 35 fractions by 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy. The primary endpoint was the 3-year overall survival (OS), and the secondary endpoints were the 3-year progression-free survival (PFS) and 3-year cause-specific survival (CSS). The Kaplan\u2013Meier method was used to calculate survival rates, and the log-rank test was used to evaluate statistical significance. A Cox proportional hazards model was used for the multivariate analysis of prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of the 49 patients was 72 (range:\u00a070\u201378) years. The median CDDP dose was 200 (40\u2013280) mg\/ m<jats:sup>2<\/jats:sup>, and 47 patients completed scheduled radiotherapy. Forty-eight patients (98.0%) had a performance status of \u2265\u20091 at the initial visit. The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8\u201390.7), 58.9% (95%CI: 42.7\u201373.3), and 85.0% (95%CI: 68.7\u201393.4), respectively. In the multivariate analysis, the cumulative CDDP dose (&lt;\u2009200 or \u2265\u2009200\u00a0mg\/m<jats:sup>2<\/jats:sup>) was a significant factor for OS (hazard ratio: 0.29 [95% CI 0.08\u20130.97], p\u2009=\u20090.044). There was one case of early mortality. Grade 3 or higher late adverse events were observed in four patients (8.2%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Weekly CDDP\u2009+\u2009RT in older patients led to good survival outcomes with an acceptable rate of adverse events. CDDP should be administered at a dose of at least 200\u00a0mg\/m<jats:sup>2<\/jats:sup> in older patients.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Retrospectively registered<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-023-00844-7","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T09:02:31Z","timestamp":1702026151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"14","author":[{"given":"Yusuke","family":"Uchinami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seijiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayuta","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"22","key":"844_CR1","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa031317","volume":"349","author":"AA Forastiere","year":"2003","unstructured":"Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091\u20138.","journal-title":"N Engl J Med"},{"issue":"4","key":"844_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y","volume":"88","author":"DJ Adelstein","year":"2000","unstructured":"Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000;88(4):876\u201383.","journal-title":"Cancer"},{"key":"844_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.753049","volume":"8","author":"J Omata","year":"2021","unstructured":"Omata J, Ueki Y, Takahashi T, Shodo R, Yamazaki K, Saijo K, Ota H, Togashi T, Sato Y, Horii A. Treatment outcomes and the safety of chemoradiotherapy with high-dose CDDP for elderly patients with head and neck squamous cell carcinoma: a propensity score matching study. Front Surg. 2021;8: 753049.","journal-title":"Front Surg"},{"issue":"8","key":"844_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.jgo.2021.05.007","volume":"12","author":"SF Oosting","year":"2021","unstructured":"Oosting SF, Desideri I, Staelens D, Caballero C, Tribius S, Simon C, Singer S, Gr\u00e9goire V, Fortpied C, Luciani A, et al. Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: results from an EORTC led survey. J Geriatr Oncol. 2021;12(8):1261\u20135.","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"844_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","volume":"97","author":"ATC Chan","year":"2005","unstructured":"Chan ATC, Leung SF, Ngan RKC, Teo PML, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. JNCI. 2005;97(7):536\u20139.","journal-title":"JNCI"},{"issue":"18","key":"844_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","volume":"40","author":"N Kiyota","year":"2022","unstructured":"Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial. J Clin Oncol. 2022;40(18):1980\u201390.","journal-title":"J Clin Oncol"},{"key":"844_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.723716","volume":"11","author":"E Haehl","year":"2022","unstructured":"Haehl E, R\u00fchle A, Spohn S, Sprave T, Gkika E, Zamboglou C, Grosu A-L, Nicolay NH. Patterns-of-care analysis for radiotherapy of elderly head-and-neck cancer patients: a trinational survey in Germany, Austria and Switzerland. Front Oncol. 2022;11: 723716.","journal-title":"Front Oncol"},{"key":"844_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejca.2016.08.013","volume":"67","author":"A Spreafico","year":"2016","unstructured":"Spreafico A, Huang SH, Xu W, Granata R, Liu C-S, Waldron JN, Chen E, Ringash J, Bayley A, Chan KKW, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Eur J Cancer. 2016;67:174\u201382.","journal-title":"Eur J Cancer"},{"issue":"10","key":"844_CR9","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1007\/s00405-017-4687-4","volume":"274","author":"A Al-Mamgani","year":"2017","unstructured":"Al-Mamgani A, Ridder MD, Navran A, Klop WM, Boer JPD, Tesselaar ME. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. Eur Arch Oto-Rhino-Laryngol. 2017;274(10):3757\u201365.","journal-title":"Eur Arch Oto-Rhino-Laryngol"},{"issue":"5","key":"844_CR10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jnci\/djy133","volume":"111","author":"JM Bauml","year":"2018","unstructured":"Bauml JM, Vinnakota R, Park Y-HA, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Stefano JD, Ciunci C, et al. Cisplatin every 3 weeks versus weekly with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck. JNCI. 2018;111(5):490\u20137.","journal-title":"JNCI"},{"issue":"2","key":"844_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/hed.23865","volume":"38","author":"S Ghosh-Laskar","year":"2016","unstructured":"Ghosh-Laskar S, Kalyani N, Gupta T, Budrukkar A, Murthy V, Sengar M, Chaukar D, Pai P, Chaturvedi P, D\u2019Cruz A, et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: results of a prospective randomized trial. Head Neck. 2016;38(2):202\u20137.","journal-title":"Head Neck"},{"issue":"3","key":"844_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1743-7563.2011.01405.x","volume":"7","author":"Z Otty","year":"2011","unstructured":"Otty Z, Skinner MB, Dass J, Collins M, Mooi J, Thuraisingam K, Sabesan S. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia Pac J Clin Oncol. 2011;7(3):287\u201392.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"844_CR13","first-page":"1185","volume":"12","author":"F Kose","year":"2011","unstructured":"Kose F, Besen A, Sumbul T, Sezer A, Karadeniz C, Disel U, Altundag O, Ozyilkan O. Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience. Asian Pac J Cancer Prev. 2011;12(5):1185\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"844_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13014-021-01966-4","volume":"16","author":"M Buglione","year":"2021","unstructured":"Buglione M, Alterio D, Maddalo M, Greco D, Gerardi MA, Tomasini D, Pegurri L, Augugliaro M, Marvaso G, Turturici I, et al. Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients. Radiat Oncol. 2021;16(1):239.","journal-title":"Radiat Oncol"},{"issue":"2","key":"844_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.anl.2012.07.002","volume":"40","author":"T Sakashita","year":"2013","unstructured":"Sakashita T, Homma A, Oridate N, Suzuki S, Hatakeyama H, Kano S, Mizumachi T, Onimaru R, Tsuchiya K, Yasuda K, et al. Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas. Auris Nasus Larynx. 2013;40(2):211\u20135.","journal-title":"Auris Nasus Larynx"},{"issue":"23","key":"844_CR16","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1200\/JCO.2004.07.962","volume":"22","author":"KK Ang","year":"2004","unstructured":"Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol. 2004;22(23):4657\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"844_CR17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","volume":"36","author":"V Noronha","year":"2017","unstructured":"Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D\u2019Cruz AK, Banavali S, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2017;36(11):1064\u201372.","journal-title":"J Clin Oncol"},{"issue":"8","key":"844_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/jjco\/hyr086","volume":"41","author":"A Homma","year":"2011","unstructured":"Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, Kano S, Sakashita T, Onimaru R, Yasuda K, et al. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol. 2011;41(8):980\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"844_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.21873\/invivo.11816","volume":"34","author":"FD Felice","year":"2020","unstructured":"Felice FD, Pranno N, Papi P, Brugnoletti O, Tombolini V, Polimeni A. Xerostomia and clinical outcomes in definitive intensity modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3D-CRT) for head and neck squamous cell carcinoma: a meta-analysis. In Vivo. 2020;34(2):623\u20139.","journal-title":"In Vivo"},{"issue":"1","key":"844_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13014-020-01666-5","volume":"15","author":"T Gupta","year":"2020","unstructured":"Gupta T, Sinha S, Ghosh-Laskar S, Budrukkar A, Mummudi N, Swain M, Phurailatpam R, Prabhash K, Agarwal JP. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiat Oncol. 2020;15(1):218.","journal-title":"Radiat Oncol"},{"issue":"2","key":"844_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jrr\/rraa130","volume":"62","author":"K Yasuda","year":"2020","unstructured":"Yasuda K, Minatogawa H, Dekura Y, Takao S, Tamura M, Tsushima N, Suzuki T, Kano S, Mizumachi T, Mori T, et al. Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients. J Radiat Res. 2020;62(2):329\u201337.","journal-title":"J Radiat Res"}],"updated-by":[{"DOI":"10.1007\/s12672-024-00868-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000}}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00844-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00844-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00844-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T15:51:12Z","timestamp":1706197872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00844-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00844-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12672-024-00868-7","asserted-by":"object"}]},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12672-024-00868-7","URL":"https:\/\/doi.org\/10.1007\/s12672-024-00868-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethical Review Board for Life Science and Medical Research in Hokkaido University Hospital (IRB-022-0028) in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects developed by the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan. All patients provided written informed consent for treatment. Consent to participate in this study was obtained in the form of an opt-out on the institutional website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}